07:55 AM EDT, 03/12/2026 (MT Newswires) -- Pulse Biosciences ( PLSE ) said Thursday it has enrolled the first patients in its first-in-human feasibility study of the nPulse Vybrance Percutaneous Electrode System to treat T1N0M0 papillary thyroid microcarcinoma.

Initial procedures were completed at Sarasota Memorial Health Care System in Florida and the University of Texas MD Anderson Cancer Center in Texas, the company said.

The company said the study, which expects to enroll 30 patients across two sites, aims to evaluate the safety and effectiveness of the system in treating thyroid cancer tumors smaller than 1.5 cm.

The nPulse system has received a 510(k) clearance from the US Food and Drug Administration for soft tissue ablation, the company said.